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have quantified the amounts of hormone secreted by the somatotropic and gonadotropic axes during this transition (1, 5, 7, 25, 30, 31) , basic neuroregulatory questions remain to be clarified about the underlying control mechanisms that drive increased hormone output (3, 24) . One means of assessing pulsatility changes on the basis of hormonal time-series data is approximate entropy (ApEn), a model-independent quantification of sequential irregularity (10, 21) . ApEn applications have allowed the endocrinologist to monitor and quantify changes in secretory patterns from a perspective complementary to that provided by output estimates or pulse detection algorithms (26) . The present study explores the hypothesis that the marked pubertal enhancement of growth hormone (GH) release in boys is accompanied by shifts in the irregularity (extent of "randomness") of GH secretory patterns, thus identifying a distinct aspect of changes in GH system control. Given that ApEn changes bear a mechanistic relationship to alterations in feedback control (discussed further below), the ensuing analyses thus allow inferential assessment of changing feedback regulation in the somatotropin release-inhibiting hormone (SRIH)/GH-releasing hormone (GHRH)-somatotropic (GH)-insulin-like growth factor I (IGF-I) axis across human puberty.
In a recent cross-sectional study of 53 boys (29) , we observed that ApEn was largest (GH dynamics most irregular) at mid-to-late puberty, with a return to maximal orderliness (smallest ApEn) thereafter toward reproductive maturity. However, this study was significantly limited by its cross-sectional study design and absence of concurrent growth analysis. Thus causality of per-subject ApEn evolution could at best be inferred only indirectly and could not be related to individual growth activity. Critically from a statistical perspective, cross-subject heterogeneity often blurs longitudinal evolutionary determinations that are more apparent on a per-subject basis. Herein, we wished to determine longitudinal per-subject profiles of ApEn evolution of GH across puberty, and to assess the time association (if any) between ApEn changes and concurrently measured linear growth rate. For this purpose, we utilize the clinical model to be described in METHODS on the basis of GH profiles collected from 23 boys studied longitudinally at 4-mo intervals over a 6-yr period as they progressed through puberty. These data provide an uncommon, possibly unprecedented, 72-point GH time series per study date for each of ϳ18 study dates for each of the 23 boys.
In addition to clarifying the evolution of ApEn transpubertally, we examine the association between ApEn values and a classical primary clinical marker of pubertal change, growth velocity (GrVel), considering both lagged and unlagged comparisons. GrVel is a well-established and relevant biological response (22) , which can be measured quite accurately via standard auxological methods.
METHODS

Clinical Protocols
This study was approved by the University of Virginia Human Investigation Committee and performed in the General Clinical Research Center. Written informed consent was obtained from a parent or guardian, and written assent was obtained from each subject. A longitudinal study was conducted of 23 prepubertal and early pubertal normally growing boys. Each volunteer was observed for Ն6 yr as he entered and progressed through pubertal development, i.e., from prepuberty, as defined by Tanner Stage I for pubic hair and genitalia, to early postpuberty (clinical Tanner Stage V for the same characteristics). At entry, each boy was within 2 SD of height for age and was growing normally. Each boy also had a normal weight for height. None of the boys had chronic illnesses or was receiving medications chronically. Data were gathered from each boy approximately every 4 mo. Height, from which GrVel was calculated, was taken mainly by a single experienced technician by use of the mean of three early morning measurements with a Harpenden stadiometer. All measurements were made to the nearest millimeter. All volunteers underwent blood sampling at 20-min intervals for 24 h on each study date (n ϭ 72 point time series). Serum GH concentrations were assayed in duplicate by immunoradiometric assay, or IRMA (Nichols Laboratories, San Juan Capistrano, CA) (6) . The minimum detectable concentration was 0.5 g/l. A detailed description of the mean intra-assay coefficients of variation (CV) across a full range of serum GH concentrations has been reported previously (4) .
Quantification of Irregularity
To quantify irregularity, we utilize ApEn, a model-independent statistic defined in Ref. 10 , with further mathematical properties and representative biological (including endocrinological) applications given in Refs. 8, 9, 12, 13, 15, 17, [19] [20] [21] 23 , and 28. ApEn assigns a nonnegative number to a time series, with larger values corresponding to greater apparent process randomness or serial irregularity and smaller values corresponding to more instances of recognizable features or patterns in the data. Two input parameters, a run length m and a tolerance window r, must be specified to compute ApEn. Briefly, ApEn measures the logarithmic likelihood that runs of patterns that are close (within r) for m contiguous observations remain close (within the same tolerance width r) on next incremental comparisons; the precise mathematical definition is given in Ref. 10 .
For this study, we calculated ApEn values for all data sets, m ϭ 1 and r ϭ 20% of the standard deviation (SD) of the individual subject time series. Normalizing r to each timeseries SD gives ApEn a translation and scale invariance to absolute serum concentration levels (12) . Additionally, ApEn provides a direct barometer of feedback system change in many coupled systems (11, 18) . Further technical discussion of mathematical and statistical properties of ApEn can be found elsewhere (14, 16) .
Analytic Strategy
Challenges in forming statistical tests. The goal of this study is to deduce typical and general characteristics of longitudinal per-subject ApEn(GH) curves transpubertally. This requires a careful analytic strategy for several reasons. First, the primary per-subject inputs are ApEn and GrVel curves (longitudinal point sets), rather than single numerical values; thus a means to aggregate these correlated data for suitable statistical testing is not straightforward. Reducing each per-subject curve to a several-parameter set via a loworder best-fit polynomial (or other elementary function) seems inappropriate, because many of the per-subject longitudinal data sets are highly nonmonotonic; i.e., they show numerous changes in direction (as in Fig. 1 ). Virtually no low-parameter models are characterized by such frequent shifts in direction (manifesting many first derivative sign changes) across time. Second, pooling the data is not so straightforward, even upon z-transformation standardization (see below), because subjects were not sampled on common dates and had differing start and end study dates relative to their date of maximal GrVel and unequal numbers of studies. Third, GrVel itself does not smoothly increase to a maximal value, thereafter subsequently showing monotonic decrease (see Fig. 1 ), so that comparisons of ApEn values to the clinical reference GrVel must at least accommodate this irregular variation.
To address these issues, we chose to analyze the data via several different and complementary, although thematically related, assessments to establish robustness and generality to the findings.
Statistical tests: ApEn(GH) evolution. On the basis of previous cross-sectional study (29) , we hypothesized that persubject ApEn values would be at a midlevel prepubertally, would tend to increase toward maximal ApEn at or near the time of maximal GrVel, and then generally and steadily decrease to a very low value at maturity, markedly smaller than the initial study value, indicating very regular GH dynamics at the final test date. To evaluate this notion in a robust manner that did not require model-based assumptions for the ApEn longitudinal curves, we performed the following calculations. First, for a given subject, denote the ApEn(GH) value on the i th study date as ApEn i and denote the GrVel value on the i th study date as GrVel i . Denote the study date for which GrVel is maximal for the subject as t max , with corresponding ApEn value ApEn vmax ; also, denote by t 1 and t fin the subject study start and final dates, respectively, with corresponding ApEn values denoted ApEn 1 and ApEn fin . Last, define t early as the study date midway between t 1 and t max , and define t late as the study date midway between t max and t fin . Thus the five study dates t 1 , t early , t max , t late , and t fin can be seen as a per-subject increasing time sequence of markers segmenting the start date-maximal growth datefinal date continuum. One-way ANOVA was then applied to evaluate the null hypothesis that the ApEn values were statistically unrelated to pubertal development across the five epochs t 1 , t early , t max , t late , and t fin . ANOVA was applied to both the raw ApEn values and to the standardized (z-transformed) ApEn values.
To further appraise the longitudinal ApEn trajectory, we also calculated 1) the percentage of dates i Ͻ t max for which ApEn i Ͼ ApEn 1 , and 2) the percentage of dates i Ͼ t max for which ApEn i Ͻ ApEn vmax . Both of these calculations were performed per subject and were subsequently pooled. Calculation 1 assesses the extent and consistency of increases in GH irregularity from study onset to the time of maximal GrVel, and calculation 2 assesses the extent and consistency of decreases in GH irregularity from the time of maximal GrVel to study completion.
Statistical tests: joint ApEn(GH), GrVel associations. We performed several sets of calculations to determine linear correlation between ApEn and GrVel. First, both per subject and subsequently pooled, we calculated the correlation between ApEn i and GrVel i . . Next, we performed led and lagged correlations and calculated the correlation between ApEn i and GrVel i-N for each of N ϭ 1, 2, 3, Ϫ1, Ϫ2, and Ϫ3.
The above overall correlation calculations have the limitation that they are affected by cross-subject variation and heterogeneity. One major hypothesis of this study is that, on a per-subject basis, ApEn correlates strongly and positively with GrVel. To assess this hypothesis by using the power of the pooled data base, yet in a manner free of cross-subject heterogeneity, we also calculated pooled overall correlations between standardized (z-transformed) ApEn i and GrVel i values. The z-transformations were performed on each subject's ApEn and GrVel values. We also performed led and lagged correlations of the pooled z-transformed data, identically to the nontransformed comparisons, for the lead and/or lag times described.
Low final date ApEn values. We tested the postulate that, and determined the degree to which, final date ApEn values are low, relative to the maximal growth date on a per-subject analysis, in a robust, nonparametric manner as follows. First, rank for each subject the final test date ApEn value among all (N) ApEn i values for that subject, denoting this as Aprank fin , which has a value between 1 (lowest) and N (largest). Then normalize this ranking by nAprank fin ϭ (Aprank fin Ϫ 1)/(N Ϫ 1), producing a range between 0 and 1. Under the null hypothesis of identical ApEn distributions on all dates, the mean nAprank fin should have a mean of 0.5 (i.e., the final date ApEn value would on average equal the median subject ApEn value). A value of nAprank fin substantially below 0.5 would indicate a final date ApEn value that is among the lowest of that subject's ApEn values.
We also calculated both the percentage of subjects for which ApEn 1 Ͼ ApEn fin and the percentage of subjects for which ApEn vmax Ͼ ApEn fin , as another pair of assessments to evaluate the hypothesized very regular GH dynamics at the final test date.
Statistical Analysis
All statistical comparisons below for discrimination between two groups employed the two-sided t-test with unknown variance. Linear correlation was assessed via the Pearson r statistic. One-way ANOVA was performed as we have discussed.
RESULTS
Representative longitudinal ApEn(GH) and GrVel plots for four boys are shown in Fig. 1. In Fig. 2 , representative GH serum concentration-time series are shown for the five indicated study dates for the boy whose longitudinal ApEn values are depicted in Fig. 1A .
As summarized in Table 1 and displayed in Fig. 3A , the comparison of raw ApEn values at the five study dates t 1 ,t early ,t max , t late , and t fin showed the largest irregularity at t early and a minimum ApEn (greatest orderliness) at t fin (ANOVA, P Ͻ 0.0001). The corresponding analyses based on the standardized (z-transformed) ApEn values show the same general pattern of evolution (Table 1, Fig. 3B ), with the same significance (P Ͻ 0.0001). In addition, the standardized data analysis indicates a slight, although not statistically significant, rise in ApEn values at t max compared with t 1 , following the maximum at t early .
To further evaluate longitudinal curve characteristics, assessing increases in GH irregularity from study onset to the time of maximal GrVel showed that, pooled, ApEn i Ͼ ApEn 1 for 64% of dates i Ͻ t max . Assessment of decreases in GH irregularity from the Values are means Ϯ SD (n ϭ 23). GH, growth hormone; ApEn, approximate entropy. Study times are defined on a per-subject and longitudinally increasing basis. t 1 , t max and t fin are, respectively, per-subject study start, maximal growth velocity, and final dates; tearly is midway between t 1 and t max ; t late is midway between t max and t fin . For each row, values identified with different superscripts differ significantly (P Ͻ 0.0001).
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time of maximal GrVel to study completion indicated that, pooled, ApEn i Ͻ ApEn vmax for 90% of dates i Ͼ t max . Table 2 indicates the linear correlation between ApEn i and GrVel i-N for each of N ϭ 1, 2, 3, Ϫ1, Ϫ2, and Ϫ3 for the pooled ensemble data, both raw and standardized. All the indicated correlations are positive, with high significance (P Ͻ 10 Ϫ10 for all but the lag ϩ3 correlations). For both standardized and raw data comparisons, the largest positive correlation between ApEn i and GrVel i-N was seen for the lag Ϫ1 data (standardized Pearson r ϭ 0.510, raw data Pearson r ϭ 0.494), with next largest positive correlation seen for the lag Ϫ2 data (standardized Pearson r ϭ 0.487, raw data Pearson r ϭ 0.467). Interestingly, both lag Ϫ1 and lag Ϫ2 data show more pronounced positive correlation than lag 0, and, importantly, all negative lag correlations (ApEn leading GrVel comparisons) were larger than any positive lag correlation.
In general, on a per-subject basis, correlation is generally moderately large and positive for each of the studied lags. Table 3 summarizes the per-subject correlations of ApEn to GrVel at the indicated lags. For time lags Ϫ3, Ϫ2, Ϫ1, and 0, 91% of the correlations were positive; for time lag 0, 87% were positive; for time lag ϩ2, 83% were positive; and for time lag ϩ3, 65% of the per-subject correlations were positive. From an alternative viewpoint, the percentages of subjects with linear correlations that were Ն0.4 (and positive) were 74% for lags Ϫ1 and Ϫ2; 65% for lags 0 and ϩ1; 56% for lag Ϫ3; 48% for lag ϩ2; and 13% for lag ϩ3.
As another calculation pertinent to determining whether ApEn leads or follows GrVel, define t Apmax as the study date with maximal ApEn value. We found that t Apmax Ͻ t max for 18 of 23 subjects, indicating that maximal ApEn values occurred earlier than maximal GrVel in 78% of subjects. As well, for three of the remaining five subjects, t Apmax is either only one or two test periods (4-8 mos) delayed from t max .
Final date ApEn values were quite low. As seen in Table 1 , cross-sectional ApEn fin ϭ 0.380 Ϯ 0.152 is approximately one-half of ApEn at t early ϭ 0.786 Ϯ 0.186. Thus the difference in the relative orderliness of GH release between early puberty to midpuberty and maturity is great. This is suggested by and consistent with the longitudinal plots shown as Fig.  1 . However, the degree to which final-date ApEn values are low (GH secretion quite regular) relative to maximal growth date is most evident by persubject analysis via calculation of the nAprank fin values described above. The mean nAprank fin (over the 23 subjects) of 0.1269, i.e., the 13th percentile, is smaller (P Ͻ 10 Ϫ10 ) than the expected mean nAprank fin of 0.5 under the null hypothesis. Moreover, for 9 of the 23 subjects, the final date had the lowest ApEn, whereas for five additional subjects, the final date was either second or third lowest.
Complementary evidence of the apparently very regular GH dynamics at the final test date is that Table 1 . By ANOVA, these 5 dates do not have identical ApEn distributions (P Ͻ 0.0001). Also, for each plot, columns identified with different super-or subscripts differ significantly (P Ͻ 0.0001). For each (raw, standardized) entry, all overall correlations were highly significant (P Ӷ 0.0001), except for lag ϩ3, for which overall raw data comparisons were significant, P Ͻ 0.05, and for which standardized comparisons were not significant at P ϭ 0.05. ApEn 1 Ͼ ApEn fin for 96% of subjects, whereas ApEn vmax Ͼ ApEn fin for 100% of subjects.
DISCUSSION
Summarizing the results, we have established that on a per-subject basis, 24-h serum GH concentration time series show pronounced variation in their sequential irregularity transpubertally, with maximal secretory disorderliness (ApEn) in pre-and mid-to-late puberty, followed by a steep decline in ApEn to maximal orderliness in postpubertal adolescence. Moreover, we determined that, in general, ApEn(GH) elevations precede GrVel increases, with a time-frame lead of one to two study periods (4-8 mo) providing the most pronounced correlations, as seen in Tables 2 and 3 . This time delay is also consistent with visual inference given by Fig. 1 , and by the finding that for 78% of boys, the date of maximal ApEn preceded that of maximal GrVel. As discussed below, there may be added clinical and experimental utility in knowing that high ApEn(GH) values typically predict high GrVel values in 4-8 mo, beyond the strictly diagnostic or confirmatory perspective that positive unlagged correlation conveys.
Statistically, per-subject standardization sharpens the (lagged and led) correlations between ApEn and GrVel by a modest, albeit significant, amount compared with raw data comparisons. More notably, one critical utility of the longitudinal study design applied here is to clarify that the hormonal dynamics precede the (accelerated) physical growth. In contrast, whereas the cross-sectional study in Ref. 29 gives qualitatively relatively similar results regarding ApEn(GH) evolution with increasing age (compare Fig. 1 of Ref. 29 with Fig. 3 here) , the data available in Ref. 29 preclude any direct comparison of hormonal dynamics, e.g., ApEn, with either GrVel or an alternative measure of physical growth.
Of course, it is imperative to note that growth is a multifactor-dependent phenomenon, and that the present analysis reflects only one correlate (GH), albeit an important one. We anticipate that, ultimately, forecasts based on multiple physiological (including hormonal) characteristics will provide enhanced accuracy in predicting periods of very rapid linear growth. To reinforce this point, in modeling the growth velocity of these boys, we have found marked effects of testosterone concentration in addition to the mean GH level (32) . In addition to age (either chronological or bone), the interaction between the mean GH level and testosterone concentration has a significant effect on the GrVel. The maximal rise in circulating testosterone concentration (and perhaps its conversion to biologically effective estrogens) precedes the maximal mean GH concentration and peak GrVel by ϳ3 mo (32), commensurate with the findings of the present study.
The longitudinal analyses allow a first-order, clinically applicable, predictive relationship between ApEn and GrVel. Across all subjects, an ApEn value of Ͼ0.8 for the 24-h GH time series (which occurred in ϳ20% of measurements) produced a mean GrVel in the subsequent measurement period of 7.33 Ϯ 2.95 cm/yr, which is significantly larger than the overall mean GrVel, which is 5.43 Ϯ 3.36 cm/yr (P Ͻ 0.0001). The GrVel of 7.33 cm/yr is the 68th percentile of pooled GrVel values. The decision rule that an ApEn value Ͼ0.8 generally predicts a high GrVel in the next 4-mo period is relatively easy to implement in potential applications, in that it is an overall population rule (rather than a per-subject determinant), thus incorporating crosssubject variation.
ApEn values of GH time series on each boy's final test date (0.380 Ϯ 0.152) were insignificantly different (P Ͼ 0.4) from comparable 20-min sampled GH ApEn values (0.425 Ϯ 0.183) in healthy young men (mean age 25 yr; age range 22-28 yr) reported in Ref. 13 . Thus we infer that, from a secretory irregularity perspective, in the present analysis, healthy postpubertal boys exhibit a fully mature GH subnetwork by the mean per-subject final study age of 17.3 (Ϯ0.9) yr.
One issue should be clarified concerning statistical study design. For statistical reasons, we chose to avoid fitting unimodal functions (or splines) to either the ApEn or GrVel longitudinal data. In principle, if such best-fit functions were established, then characteristics of each curve, such as the date of maximal growth rate from such a GrVel curve, could be inferred algebraically. However, given the nonmonotonicity of each of ApEn and GrVel as a function of time (see comments in Analytical Strategy), we expect that such fitting procedures could produce somewhat equivocal or arbitrary results. Indeed, the ApEn-GrVel correlations as assessed herein provided a robust, and we believe biologically realistic, quantification of the association of ApEn and transpubertal growth.
Neuroendocrine Considerations
We have previously linked ApEn changes to a mechanistic understanding via theoretical modeling studies (11, 18) . In particular, for diverse mathematical network models, greater regularity (lower ApEn) typically corresponds to greater component and subsystem autonomy and, conversely, greater irregularity corresponds to increased external influences, increased coupling strength, and/or accelerated positive feedback. On the basis of the present analysis, we thus propose that the increased GH irregularity observed before and near peak GrVel reflects more critical interacting factors within the GH feedback axis, or a greater intensity of particular interactions, e.g., among GHRH-SRIH- (29) support the hypothesis that estradiol in particular, or testosterone acting after its aromatization to estradiol, can govern the feedback regulation of GH release during puberty and in young adulthood. In the first study, clinical experiments in prepubertal girls with gonadal dysgenesis (Turner's syndrome) showed that treatment with a small dose of ethinyl estradiol orally for 5 wk increases GH ApEn significantly. In the second study, ApEn of GH increased in response to short-term parenteral testosterone administration to clinically prepubertal boys with constitutionally delayed adolescence, yet showed no increase upon treatment with a nonaromatizable androgen, 5 ␣-dihydrotestosterone (DHT).
A minority of children born with intrauterine growth retardation have a propensity for the metabolic syndrome as adults (2) . Theoretically, the disordered intrauterine environment had reprogrammed intermediary metabolism. Large doses of GH given for 2 yr leads to marked catch-up growth in the majority of those who fail to catch up on their own. Those that do catch up to their target height percentile often remain along that growth trajectory even without additional GH. One interpretation of this observation is that the metabolic syndrome is again reprogrammed toward normalcy by this treatment. It is likely that altering GH secretion is pivotal in this extrauterine treatment phase. Analyses such as those discussed in this report may then provide explicit numerical support of the hypothesis that feedback mechanisms have been altered in this metabolic reprogramming.
Potential Applications and Follow-Up Studies
Some follow-up studies are suggested by the present findings. For example, clinically one would like to predict, as well as possible, stature at maturity, and as an important intermediate point, the time of maximal linear growth. In addition to GH input, one might develop a multivariate predictive model utilizing concurrent (e.g., testosterone, IGF-I, and/or estradiol) measurements when they are available. Furthermore, if time-series data per study date became available for two or more hormones, e.g., GH and testosterone, one could calculate cross-ApEn values (19, 21) on paired hormonal time series to determine changes in bihormonal synchrony across the peripubertal years. Such information could aid in determining effective intervention modalities, e.g., whether and when treatment with testosterone would be necessary to augment linear growth.
Additionally, there may be practical applicability in determining whether administering GH on the basis of some secretory irregularity threshold, e.g., current ApEn(GH) Ͼ0.8, achieves more efficient growth per unit GH dosage compared with dosages given either at random times or uniformly over a longer regimen.
Whether the ApEn variations in GH across pubertal development are unique to the somatotropic axis, or also apply to other hormonal subsystems transpubertally, is not yet known. An earlier finding is that aging well beyond the young adult years results in a slowly increasing rise in GH ApEn (28) , indicating a progressively more disorderly GH release pattern, also seen for luteinizing hormone/testosterone (19) , ACTH/cortisol (27) , and insulin (8) . Hence, one could hypothesize that ApEn changes in hormonal secretory patterns may in part detect broader alterations in neuroregulatory control.
The present study was conducted in healthy boys only. Accordingly, the extent to which analogous secretory irregularity changes are present in boys with growth-related pathophysiology, in young girls in the peripubertal time frame, and in nonhuman species remains a very important, yet open, area for future research.
